RESEARCH AND CLINICAL INSIGHTS FROM BAYLOR SCOTT & WHITE PRESENTED AT ACC 2024 ANNUAL SCIENTIFIC SESSION & EXPO

The American College of Cardiology and the World Heart Federation's World Congress of Cardiology (WCC) bring members of the global cardiovascular community together for ACC.24, in Atlanta, Georgia, April 6-8. The ACC.24 is the largest gathering of clinicians, researchers and innovative products and services providers under one roof, giving members of the cardiovascular community access to knowledge, resources and collaborative opportunities to help advance care options and improve outcomes for patients worldwide.

Baylor Scott & White Health clinicians and researchers from Baylor Scott & White Research Institute, Baylor University Medical Center at Dallas, Baylor Scott & White The Heart Hospital at Plano and Baylor Scott & White Medical Center – Temple will be involved in more than 45 presentations, scheduled talks, education sessions and panel discussions.

A snapshot of talks and presentations with Baylor Scott & White involvement can be found below. Additional details about the meeting can be found on the event website.

 

 

 

FEATURED PRESENTATIONS AND SESSIONS HIGHLIGHTING CARDIOVASCULAR RESEARCH

SATURDAY, APRIL 6, 2024

SESSION 601-06: Fellows Bootcamp: Emerging Concepts in Structural Heart Disease

  • Panelist: Molly Szerlip, MD

  • Time: 8:30 - 9:45 a.m. EST

  • Session Info: In this session, structural heart disease experts will present the current data on hot structural topics, including septal reduction, expanding indication for TAVR and percutaneous tricuspid treatments.

  • For More Information: Click here

SESSION 601-09: Mitral and Tricuspid Interventions: How and When to Repair and Replace

  • Panelist: Molly Szerlip, MD

  • Time: 8:45 - 8:55 a.m. EST

  • Session Info: In this session, structural heart disease experts will present the current data on hot structural topics, including septal reduction, expanding indication for TAVR and percutaneous tricuspid treatments.

  • For More Information: Click here

SESSION 402-10: Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial

  • Author: Javed Butler, MD

  • Time: 9:50 - 10:02 a.m. EST

  • Abstract/Study Purpose: Under Embargo

  • For More Information: Click here

SESSION 1002-09: Total and Cause-Specific Healthcare Costs Following Hospitalization For Heart Failure With Reduced vs. Mildly Reduced/Preserved Ejection Fraction

  • Research Collaborator: Javed Butler, MD

  • Time: 10:15 - 10:25 a.m. EST

  • Abstract/Study Purpose: The degree to which total and components of healthcare costs vary for heart failure (HF) with reduced vs mild reduced/preserved ejection fraction (EF) is unclear. Understanding cause-specific costs could inform the expected cost-offset with implementation of HF therapies across the EF spectrum.

  • For More Information: Click here

SESSION 1221-046: Emergency Valve-In-Valve Transcatheter Aortic Valve Replacement for Severe Aortic Insufficiency Masquerading as STEMI

  • Author: Samuel Dugger, MD

  • Time: 10:45 - 11:30 a.m. EST

  • Abstract/Study Purpose: Bioprosthetic aortic valves (AV) deteriorate with age, sometimes necessitating urgent intervention.

  • For More Information: Click here

SESSION 1251-189: Aortic-Valve Stenosis: Finding From the Examination of Operatively-Excised Stenotic Aortic Valves Over a 60-Year-Period

  • Author: Minseob Jeong, MD

  • Time: 11:45 a.m. - 12:30 p.m. EST

  • Abstract/Study Purpose: Predictably successful AVR (aortic valve replacement) began in 1960. One of us began examining operatively excised aortic valves in 1963 and each year thereafter until 2023. This report describes the structure of the 3,611 operatively excised valves, the changes that occurred in the earlier decades versus the later decades.

  • For More Information: Click here

SESSION 501-01: April Adventure: Vexing Valves

  • Co-Chair: Michael Mack, MD

  • Time: 12:00 - 1:15 p.m. EST

  • Session Info: Featuring three debates, this session will address challenging questions that arise in the care of patients with valve disease. New this year is a segment on pulmonic valve disease.

  • For More Information: Click here

SESSION 613: From Expanding the Donor Pool to Navigating the Transplant System as a Physician and Caregiver: A Potpourri of Hot Topics in Heart Transplant

  • Co-Chair: Shelley Hall, MD

  • Time: 12:00 - 1:15 p.m. EST

  • Session Info: This is a session designed to cover hot topics in heart transplant. From expanding the donor pool, to the allocation system and its effects on who receives a heart transplant, to health policy. The session will include a real case of a physician, caregiver, and health equity expert's experience navigating the transplant system.

  • For More Information: Click here

SESSION 201: Interventional Live Cases I: Peripheral Cases From Emory Heart and Vascular Center and Saint Luke's Mid America Heart Institute

  • Co-Chair: Subhash Banerjee, MD

  • Time: 12:00 - 1:15 p.m. EST

  • For More Information: Click here

SESSION 1266-144: Management of Antiplatelet Regimen During Surgical Procedures: A Report from the MARS Registry

  • Author: David Vasquez, MD

  • Time: 12:45 - 1:30 p.m. EST

  • Session Info: There are several differences in current clinical practice patterns regarding perioperative management of post-percutaneous coronary intervention (PCI) patients on dual antiplatelet therapy (DAPT) undergoing surgery.

  • For More Information: Click here

SESSION 202: Interventional Live Cases II: Structural Cases From Henry Ford Hospital and Emory Heart and Vascular Center

  • Co-Chair: Molly Szerlip, MD

  • Time: 1:45- 3:15 p.m. EST

  • For More Information: Click here

SESSION 1294-226: Secondary Prevention and Recurrent Cardiovascular Events Among South Asian Individuals: Insights From the Baylor Scott & White Dilwale Registry

  • Author: Michael Vu, DO

  • Time: 1:45 - 2:30 p.m. EST

  • Abstract/Study Purpose: South Asians (SAs) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). Despite advances in pharmacologic therapy and preventive interventions, ASCVD is a leading cause of morbidity and mortality among SAs.

  • For More Information: Click here

SESSION 1300-103: A Challenging Case of Transcatheter Aortic Valve-In-Valve Freestyle Aortic Valve as a Bridge to a REDO Surgical Aortic Valve Replacement

  • Author: Mohammed Salih, MD

  • Time: 2:45 - 3:30 p.m. EST

  • Abstract/Study Purpose: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has emerged as an alternative to redo surgical aortic valve replacement (SAVR) in treating failed bioprosthetic valves. Third-time TAVR, however, remains an uncommon procedure.

  • For More Information: Click here

SESSION 1300-105: Successful Percutaneous Closure of Multiple Giant Coronary Artery Fistulate to Coronary Sinus Presented with Acute Decompensated Heart Failure Symptoms

  • Author: Mohammed Salih, MD

  • Time: 2:45 - 3:30 p.m. EST

  • Abstract/Study Purpose: Coronary artery fistula (CAF) is generally rare with a reported incidence of 0.1-0.2% of congenital heart diseases. Although usually asymptomatic, it can sometimes present with significant symptoms.

  • For More Information: Click here

SESSION 1300-106: Securing the Plug; A Challenging Case of a Complex Mitral Paravalvular Leak Closure

  • Author: Mohammed Salih, MD

  • Time: 2:45 - 3:30 p.m. EST

  • Abstract/Study Purpose: Paravalvular leak (PVL) incidence after mitral surgical replacement ranges from 7% to 17%. Percutaneous PVL closure has shown excellent results with a low rate of complications, and nowadays it's considered the first option in selected patients in some experienced centers.

  • For More Information: Click here

SESSION 1047-05: A Rare Case of Adult Anomalous Left Coronary Artery Arising From The Pulmonary Artery (ALCAPA)

  • Author: Mica Alex, MD

  • Time: 3:45 - 3:55 p.m. EST

  • Abstract/Study Purpose: Symptoms in infancy such as colic and food intolerance are often benign, but can also be caused by a rare congenital abnormality called ALCAPA. This condition can lead to myocardial ischemia, congestive heart failure, or sudden cardiac death, and is normally identified in infancy but here we present an adult with ALCAPA.

  • For More Information: Click here

SESSION 1047-05: Antero-Posterior Mitral Annular Diameters And Clinical Outcomes In The COAPT Trial

  • Research Collaborator: Michael Mack, MD

  • Time: 3:45 - 3:55 p.m. EST

  • Abstract/Study Purpose: In the randomized COAPT trial, mitral transcatheter edge-to-edge repair (TEER) reduced mitral regurgitation, heart failure hospitalizations (HFH), and mortality and improved quality of life in patients with severe secondary mitral regurgitation (SMR) compared with guideline-directed medical therapy (GDMT) alone through 5 years. A prior posthoc analysis of baseline echocardiographic mitral valve geometric parameters showed that increasing anteroposterior mitral annular diameter (APMAD) was the sole independent predictor of the composite endpoint of all-cause mortality or HFH at 2 years. Given the relationship between the mitral annulus and leaflets, and that annuloplasty can be a surgical treatment for SMR, we examined the association of baseline APMAD on long-term clinical outcomes and change in annular dimensions.

  • For More Information: Click here

SESSION 1320-001: Actinomyces Prosthetic Valve Infective Endocarditis Presenting With Valve Stenosis

  • Author: Adegbola Oluwole, MD

  • Time: 3:45 - 4:30 p.m. EST

  • Abstract/Study Purpose: Infective endocarditis usually leads to valve destruction with valvular regurgitation and Actinomyces endocarditis is rare.

  • For More Information: Click here

SESSION 1320-007: Infected Coronary Pseudo Aneurysm

  • Author: Modar Alom, MD

  • Time: 3:45 - 4:30 p.m. EST

  • Abstract/Study Purpose: Coronary artery pseudoaneurysms, often seen post-percutaneous coronary intervention (PCI) and can lead to serious conditions like sepsis. We report a rare care of Coronary Pseudoaneurysm with no previous PCI that got infected leading to bacteremia and sepsis.

  • For More Information: Click here

SESSION 1325-169: Temporal Trends and Contemporary Outcomes of Valve-In-Valve Transcatheter Aortic Valve Replacement: A Single Healthcare System Experience

  • Author: Ghadi Moubarak, MD

  • Time: 3:45 - 4:30 p.m. EST

  • Abstract/Study Purpose: Valve-in-valve (ViV) transcatheter aortic replacement (TAVR) has been a disruptive procedure with wide variability in procedure performance and patient outcomes. We embarked on a systemwide approach to standardize processes of care and improve outcomes.

  • For More Information: Click here

SESSION 1325-171: Transcatheter Aortic Valve-In-Valve Implantation Using a Balloon-Expandable Valve in Patients With Degenerated Stented Versus Stentless Aortic Bioprothesis

  • Author: Ghadi Moubarak, MD

  • Time: 3:45 - 4:30 p.m. EST

  • Abstract/Study Purpose: Valve-in-valve (ViV) transcatheter aortic replacement (TAVR) has been mostly performed in failing stented bioprosthetic valves; stentless bioprostheses are more challenging for transcatheter therapy. We sought to compare outcomes after TAVR in stented vs. stentless bioprosthesis.

  • For More Information: Click here

SESSION 403-12: Once-Weekly Semaglutide In Patients With Heart Failure With Preserved Ejection Fraction, Obesity And Type 2 Diabetes: Main Results From The Step-hfpef Dm Trial

  • Research Collaborator: Javed Butler, MD

  • Time: 4:27 - 4:39 p.m. EST

  • Abstract/Study Purpose: Under Embargo

  • For More Information: Click here

SUNDAY, APRIL 7, 2024

SESSION 504: April Adventure: Top Interventional Trials of 2023

  • Co-Chair: Subhash Banerjee, MD

  • Time: 8:00 - 9:30 a.m. EST

  • For More Information: Click here

SESSION 1054: From Bench to Bedside: Novel Findings in Ischemic Heart Disease

  • Moderator: Robert Widmer, MD

  • Time: 9:00 - 10:30 a.m. EST

  • For More Information: Click here

SESSION 658: Emerging Therapies In Vascular Disease

  • Co-Chair: Subhash Banerjee, MD

  • Time: 9:45 - 11:00 a.m. EST

  • For More Information: Click here

SESSION 1360-007: A Complicated Case of Fractional Flow Reserve and Instantaneous Wave-Free Ratio Discordance

  • Author: Ghadi Moubarak, MD in collaboration with Radhika Vaishnav, MD

  • Time: 10:15-11:00 a.m. EST

  • Abstract/Study Purpose: Instantaneous wave-free ratio (IFR)-guided coronary revascularization has similar outcomes to the fraction flow reserve (FFR)-guided revascularization strategy. When FFR and IFR are in discordance, decision-making and clinical outcomes become difficult.

  • For More Information: Click here

SESSION 909-12: Clinical Outcomes With Intra-Aortic Balloon Pump in Cardiogenic Shock Due to Acute Myocardial Infarction or Heart Failure: A Report From The Cardiogenic Shock Working Group

  • Research Collaborator: Jaime Hernandez-Montfort, MD

  • Time: 10:47 - 10:57 a.m. EST

  • Abstract/Study Purpose: Intra-aortic balloon pumps (IABPs) are the most used mechanical circulatory support devices (MCSD) in patients with cardiogenic shock (CS). Real world data evaluating clinical outcomes in patients supported with IABP remain limited by small numbers. Moreover, there is lack of correlation of outcomes for the use of IABP in CS due to acute myocardial infarction (MI-CS) vs heart failure (HF-CS).

  • For More Information: Click here

SESSION 1063-03: Clinical Outcomes and the Impact of SCAI Stage Among Protekduo Right Ventricular Assist Device Recipients With Cardiogenic Shock: A Report From the Cardiogenic Working Group

  • Author: Jaime Hernandez-Montfort, MD

  • Time: 11:00 - 11:10 a.m. EST

  • Abstract/Study Purpose: The ProtekDuo is a dual-lumen cannula used to provide mechanical circulatory support (MCS) for right heart failure (RHF) in patients with cardiogenic shock (CS). It can be used for primary RHF or in those with biventricular failure, concomitant with an LV support device. Real world data evaluating outcomes in patients supported with the ProtekDuo remain limited by small numbers and a lack of correlation with outcomes.

  • For More Information: Click here

SESSION 1381-043: Intracardiac Echocardiography for Guiding Balloon Mitral Valvuloplasty

  • Author: Mohammed Salih, MD

  • Time: 11:15 a.m. - 12:00 p.m. EST

  • Abstract/Study Purpose: Percutaneous balloon mitral valvuloplasty (PBMV) is an established treatment for rheumatic mitral stenosis (MS). It is historically guided by fluoroscopy and TEE, and the role of intracardiac echocardiogram (ICE) guidance is not well defined.

  • For More Information: Click here

SESSION 1381-069: An Interventional Conundrum: A Complex Case of Acute Submassive Pulmonary Embolism and LV Thrombus in the Setting of Acute Renal Failure

  • Author: Priyamvada Pillai, MD

  • Time: 11:15 a.m.-12:00 p.m. EST

  • Abstract/Study Purpose: Submassive Pulmonary Embolism in renal failure is a therapeutic challenge. We present a challenging case of mechanical thrombectomy of extensive bilateral submissive PE in the setting of renal failure.

  • For More Information: Click here

SESSION 678: 2024: A Valve Odyssey

  • Panelist: Robert Smith, MD

  • Time: 12:15 - 1:30 p.m. EST

  • Session Info: In the increasingly complex landscape of modern clinical cardiology practice, this session aims to provide historical perspective on the diagnosis and management of valve disease, with a look toward future challenges and opportunities. TED-style talks will be accompanied by extensive panel discussion.

  • For More Information: Click here

SESSION 680-02: Viscious Venn Diagram: CAD, Valvular Disease, LV Dysfunction

  • Co-Chair: Michael Mack, MD

  • Time: 2:00 - 3:15 p.m. EST

  • Session Info: Two overview presentations on risk stratification and imaging followed by a case-based session that will cover challenging cases with patients with multiple co-morbidities. Fellows will present a case with a specifically challenging cardiovascular condition.

  • For More Information: Click here

SESSION 507: April Adventure: Critical Care Cardiology Family Feud

  • Participant: Shelley Hall, MD

  • Time: 2:00 - 3:15 p.m. EST

  • Description: Let's play the Feud. Families that feud together stay together. This session is designed to bring together stakeholders in the field of Critical Care Cardiology for a "friendly" educational game while providing attendees with an opportunity to understand and comment on the dynamics that have and continue to transform the CICU.

  • For More Information: Click here

SESSION 703: Parachuting Into the Future: Advances in Mitral Valve Disease

  • Co-Chair: Molly Szerlip, MD

  • Time: 2:00 - 3:15 p.m. EST

  • Session Info: This session will highlight challenges frequently encountered in care of patients with mitral valve disease, including management of atrial functional mitral regurgitation.

  • For More Information: Click here

SESSION 1440-072: Concurrent Presentation of Cardiac Fabry Disease and Hypertrophic Cardiomyopathy in a Single Patient

  • Author: Youssef Yaacoub, MD

  • Time: 2:15 - 3:00 p.m. EST

  • Abstract/Study Purpose: Anderson's Fabry disease (AFD) and hypertrophic cardiomyopathy (HCM) are both inherited genetic disorders that can lead to myocardial hypertrophy. Their coexistence in the same patient is extremely rare and raises questions about potential interactions and common pathways.

  • For More Information: Click here

SESSION 408-06: Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial

  • Author: Javed Butler, MD

  • Time: 2:15 - 2:20 p.m. EST

  • Abstract/Study Purpose: Under Embargo

  • For More Information: Click here

MONDAY, APRIL 8, 2024

SESSION 411-08: A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

  • Research Collaborator: Javed Butler, MD

  • Time: 8:30 - 8:40 a.m. EST

  • Abstract/Study Purpose: Under Embargo

  • For More Information: Click here

SESSION 1108: Complex Clinical Cases: Pulmonary Vascular Disease and Vascular Medicine

  • Moderator: Robert Widmer, MD

  • Time: 9:00 - 10:30 a.m. EST

  • For More Information: Click here

SESSION 1105-05: Temporal Trends of Vasopressor and Inotrope Use in Cardiogenic Shock Working Group Report

  • Research Collaborators: Shelley Hall, MD and Jaime Hernandez-Montfort, MD

  • Time: 9:15 - 9:25 a.m. EST

  • Abstract/Study Purpose: There remains a paucity of the temporal use and total vasoactive medication requirements for cardiogenic shock (CS) patients in the contemporary era.

  • For More Information: Click here

SESSION 1105-09: Impact of Cumulative Vasopressor and Inotrope Medications on Outcomes in Cardiogenic Shock: A Cardiogenic Shock Working Group Report

  • Research Collaborators: Shelley Hall, MD and Jaime Hernandez-Montfort, MD

  • Time: 9:45-9:55 a.m. EST

  • Abstract/Study Purpose: There is a paucity of data on the prognostic implication of vasoactive medications on mortality in cardiogenic shock (CS).

  • For More Information: Click here

SESSION 1480-007: From Images to Insight: Uncovering the Diagnosis of a Primary Cardiac Tumor in an HIV Positive Patient

  • Author: Priyamvada Pillai, MD in collaboration with Zarnaz Mahmood, MD

  • Time: 9:45 - 10:30 a.m. EST

  • Abstract/Study Purpose: Primary cardiac tumors are rare and pose a diagnostic challenge owing to varied clinical presentations and occasional inconclusive histological findings, requiring a high index of suspicion, particularly in the immunocompromised like HIV patients.

  • For More Information: Click here

SESSION 1480-026: Mad About MAD (Mitral Annular Dysjunction)

  • Author: Youssef Yaacoub, MD

  • Time: 9:45 - 10:30 a.m. EST

  • Abstract/Study Purpose: Mitral valve prolapse (MVP) has been associated with malignant ventricular arrhythmias and sudden cardiac death (SCD) with unknown etiology, it was noted that Papillary muscle fibrosis and mitral annular disjunction (MAD) are linked to increase risk. MAD results in an abnormal motion of the mitral annulus, and is associated with increased risk of arrhythmias and is therefore an integral component of the arrhythmic MVP (AMVP) complex.

  • For More Information: Click here

SESSION 1099-09: Remove Follow-Up In A Heart Failure Pragmatic Trial: Insights From The Connect-HF

  • Research Collaborator: Javed Butler, MD

  • Time: 9:45 - 9:55 a.m. EST

  • Abstract/Study Purpose: Randomized controlled trials typically require study-specific visits, which can burden participants and sites. Remote follow-up holds promise for reducing costs and enhancing the pragmatism of trials.

  • For More Information: Click here

SESSION 1528-167: IVUS Guided PCI: A Method to Improve Outcomes for Patients with Multivessel Disease

  • Author: Jacob Powell, MD

  • Time: 11:45 a.m. - 12:30 p.m. EST

  • Abstract/Study Purpose: CAD occurs when atherosclerotic plaque formation creates variable degrees of stenosis in the coronary arteries. If the stenosis is severe or sudden, myocardial injury or infarction can result. The primary goal of interventional treatment is to restore adequate blood flow to myocardial tissue. Two invasive methods are currently available, percutaneous coronary intervention (PCI) and coronary artery bypass (CABG). PCI can be accompanied by intravascular imaging using intravascular ultrasound (IVUS), which aims to increase physicians' understanding of vessel characteristics to optimize stent implantation. It is currently unknown if IVUS-guided PCI (IGP) technology will improve one-year outcomes when compared to PCI standard of care and CABG in patients with multivessel disease.

  • For More Information: Click here

SESSION 750-02: The Monsoon Is Coming: Understanding and Mitigating Cardiometabolic Risk in South Asians

  • Co-Chair: Anandita Kulkarni, MD

  • Time: 12:45 - 2:00 p.m. EST

  • Session Info: South Asians living in the US have a higher prevalence of ASCVD than other ethnicities. This session will highlight reasons for these disparities in strategies on how to manage these very high-risk patients.

  • For More Information: Click here

SESSION 764-05: Closing the Gap: Understanding and Addressing Adherence and Persistence with Lipid-Lowering Medications

  • Panelist: Anandita Kulkarni, MD

  • Time: 2:30 - 3:45 p.m. EST

  • Session Info: Despite major advances in therapeutic options to address LDL-C and ASCVD risk, use of these agents in clinical practice remains low. Reasons for this include system, clinician, and patient-level barriers. This session will review reasons for nonadherence, including statin associated muscle systems, discuss strategies to overcome inertia and economic factors related to lipid management.

  • For More Information: Click here

SESSION 764-10: Conquering the Challenge: Strategies for Managing Statin-Associated Muscle Symptoms

  • Panelist: Anandita Kulkarni, MD

  • Time: 3:01 - 3:14 p.m. EST

  • Session Info: Despite major advances in therapeutic options to address LDL-C and ASCVD risk, use of these agents in clinical practice remains low. Reasons for this include system, clinician, and patient-level barriers. This session will review reasons for nonadherence, including statin associated muscle systems, discuss strategies to overcome inertia and economic factors related to lipid management.

  • For More Information: Click here

© 2024 Baylor Scott & White Health. All Rights Reserved.
Privacy and Patient Rights Terms of Use Notice of Non-Discrimination
3500 Gaston Ave., Dallas, TX 75246-2017 | 1.844.BSW.DOCS (1.844.279.3627)